Advocates in Canberra have called on the government to
urgently subsidise new, advanced treatments for hepatitis C, saying each
month they delay about 50 people die from the condition.
Pharmaceutical Benefits Advisory Committee recommended on April 24
that three new antiviral medications, designed to treat hepatitis C, be
considered for addition to the Pharmaceutical Benefits Scheme.
Alliance for Harm Minimisation and Advocacy manager Sione Crawford, who
lives with hepatitis C, said the difference between the new and old
drugs was like "night and day".
Labels: access to drugs, australia, Pharmaceutical Benefits Scheme (PBS)